FDA Considers Easing Industry Burden In AF Ablation Catheter Trial Design
This article was originally published in The Gray Sheet
Executive Summary
FDA may be willing to accept a reduction of symptoms as the primary endpoint for atrial fibrillation ablation catheter clinical trials, according to CDRH Cardiac Electrophysiology & Monitoring Devices Branch Medical Officer Randall Brockman, MD